- Pharma Profits Continue to Dwarf R&D Spending as Pressure MountsWith the repeal of Obamacare on life support, the furor over rising prescription drug prices and President Donald Trump’s support for the cause could end up filling the vacant crossroads where bipartisanship meets change.
- Regulatory Recon: AZ’s Tagrisso First to be Approved Under China’s Priority Review Pathway; House Hearing on Device User Fees Set for Tuesday (27 March 2017)
- About GRP
- Resource Center
- RI Platform
- Contact Us